The Paul-Ehrlich-Institut wishes Merry Christmas and a Happy New Year 2015
The year is drawing to a close, in which the Paul-Ehrlich-Institut has sucessfully faced the existing regulatory, scientific and policy challenges in an international setting. The availibility of safe and effective biological medicines – and thus the health of the general public – has been our main concern at all times.
The Paul-Ehrlich-Institut approves clinical trial with Ebola vaccine candidate
The first clinical phase I trial to be conducted in Germany with the candidate vaccine rVSV-ZEBOV will start within the next few weeks. The trial will enrol healthy adults, possibly including healthcare personnel involved in the care of Ebola patients in Germany or Africa, and investigate the potential benefit of the vaccine candidate as well as its risks.
Paul-Ehrlich-Institut and Robert Koch-Institut support the clinical development of vaccines and therapeutic medicines against Ebola
On August 8, 2014, the WHO declared the ongoing Ebola epidemic an International Public-Health Emergency. In recent years, several promising approaches to combat Ebola virus infection have emerged as a result of research and development on vaccines and therapeutic medicines. In non-clinical experiments protection of naïve animals from infection or reduction of disease severity in already infected animals has been shown. Now is the time to accelerate clinical development of these candidate vaccines and therapeutics by moving them into clinical trials involving human participants. This is unrelated to the compassionate use applications to save individual patients. The Paul-Ehrlich-Institut offers regulatory support to interested parties via early advice by its Innovation Office.